Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Celsion Granted SFDA Approval for China Cancer Trial

publication date: Oct 16, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Celsion Corporation has received SFDA approval to include China sites in its global Phase III clinical trial of a new liver cancer therapy, ThermoDox. ThermoDox is a liposomal encapsulation of doxorubicin, a commonly used chemotherapy drug; the formulation is designed to release its active ingredient when heated. Celsion said China’s acceptance of the trial is very significant due to the size of China’s market. China is home to over half of the world’s HCC patients. More details...

Stock Symbol: (NSDQ: CLSN)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors